Related Experiment Videos
[Marrow transplantation in leukemia-recent trends]
Summary
Hematopoietic stem cell transplantation offers a cure for children with acute leukemia who relapse after chemotherapy. Early transplantation with an HLA-identical sibling donor is the preferred treatment due to reduced complications.
Area of Science:
- Pediatric Oncology
- Hematology
- Immunology
Context:
- Conventional chemotherapy cures 50-60% of childhood acute leukemia.
- Relapse remains a significant challenge, leading to mortality in 40-50% of cases.
- Alternative therapeutic strategies are crucial for improving outcomes.
Purpose:
- To evaluate the efficacy and safety of hematopoietic stem cell transplantation (HSCT) in pediatric acute leukemia.
- To compare HSCT with conventional chemotherapy as an early therapeutic intervention.
- To assess the impact of Graft-versus-Host Disease (GvHD) and immunosuppressive therapy on HSCT outcomes.
Summary:
- Hematopoietic stem cell transplantation (HSCT) from an HLA-identical sibling is a viable therapeutic option for pediatric acute leukemia.
- Early HSCT demonstrates superiority over conventional chemotherapy in adults and is associated with fewer severe complications.
- The incidence of severe Graft-versus-Host Disease (GvHD) is reduced with early transplantation and the use of Cyclosporin-A.
Impact:
- HSCT is recommended as the primary treatment for pediatric acute leukemia patients with an HLA-identical sibling donor.
- This approach offers a potential cure for patients who would otherwise face a high risk of relapse and death.
- Advancements in HSCT and immunosuppressive therapy have improved patient tolerance and reduced major complications, making it a well-defined and effective treatment.